The pandemic continues to cause unprecedented disruption across industries worldwide.
Get detailed insights regarding the impact of COVID-19 on the market.
The global 3D cell culture market reached a value of US$ 1,746 Million in 2021. Looking forward, IMARC Group expects the market to reach US$ 4,123 Million by 2027, exhibiting a CAGR of 15.28% during 2022-2027. Keeping in mind the uncertainties of COVID-19, we are continuously tracking and evaluating the direct as well as the indirect influence of the pandemic on different end use sectors. These insights are included in the report as a major market contributor.
3D cell culture refers to an in-vitro technique used for developing biological cells in a three-dimensional artificial environment. The cell cultures replicate the structure of complex cellular matrices and mimic tissue and organ-specific microarchitectures. They are further observed to gain insights regarding the interaction of cells with the natural environment during radiotherapy, chemotherapy and antibody-based immunotherapy. 3D cell cultures are commonly used in magnetic, bio-printed, scaffold-based and scaffold-free variants. They are widely used for drug screening, development of stem cell therapies and cancer research. In comparison to the traditionally used 2D cell cultures, 3D cell cultures provide an improved simulation of conditions in a living organism and are independent of other cells and tissues.
The increasing prevalence of chronic medical ailments across the globe is one of the key factors driving the growth of the market. The rising preference for personalized medicines among healthcare providers and patients is also providing a thrust to the market growth. 3D cell cultures are extensively used for the development of cancer treatments, stem cell research, drug discovery, toxicology testing and tissue engineering. Moreover, as the coronavirus disease (COVID-19) continues to spread across the globe, there has been a significant increase in the utilization of scaffold-based 3D cell cultures for the discovery and bio-fabrication of antiviral drugs and novel therapeutics. Additionally, the development of advanced microfluidic-based 3D cell cultures with improved cell viability, morphology, proliferation and differentiation is contributing to the growth of the market. Other factors, including extensive research and development (R&D) activities in the field of biotechnology, along with the increasing requirements for effective alternatives to animal testing, are anticipated to drive the market toward growth.
IMARC Group provides an analysis of the key trends in each sub-segment of the global 3D cell culture market, along with forecasts at the global, regional and country level from 2022-2027. Our report has categorized the market based on product, application and end user.
Breakup by Product:
Breakup by Application:
Breakup by End User:
Breakup by Region:
The competitive landscape of the industry has also been examined along with the profiles of the key players being 3D Biotek LLC, Advanced Biomatrix Inc., Avantor Inc., CN Bio Innovations Limited, Corning Incorporated, Emulate Inc., InSphero AG, Lonza Group AG, Merck KGaA, Promocell GmbH, Synthecon Inc and Thermo Fisher Scientific Inc.
|Base Year of the Analysis||2021|
|Segment Coverage||Product, Application, End User, Region|
|Region Covered||Asia Pacific, Europe, North America, Latin America, Middle East and Africa|
|Countries Covered||United States, Canada, Germany, France, United Kingdom, Italy, Spain, Russia, China, Japan, India, South Korea, Australia, Indonesia, Brazil, Mexico|
|Companies Covered||3D Biotek LLC, Advanced Biomatrix Inc., Avantor Inc., CN Bio Innovations Limited, Corning Incorporated, Emulate Inc., InSphero AG, Lonza Group AG, Merck KGaA, Promocell GmbH, Synthecon Inc and Thermo Fisher Scientific Inc.|
|Customization Scope||10% Free Customization|
|Report Price and Purchase Option||Single User License: US$ 2499
Five User License: US$ 3499
Corporate License: US$ 4499
|Post-Sale Analyst Support||10-12 Weeks|
|Delivery Format||PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request)|
The global 3D cell culture market was valued at US$ 1,746 Million in 2021.
We expect the global 3D cell culture market to exhibit a CAGR of 15.28% during 2022-2027.
The rising prevalence of chronic medical ailments, along with the growing utilization of 3D cell culture for developing cancer treatments, stem cell research, drug discovery, etc., is primarily driving the global 3D cell culture market.
The sudden outbreak of the COVID-19 pandemic has led to the increasing adoption of scaffold-based 3D cell cultures for the discovery and bio-fabrication of antiviral drugs and novel therapeutics against the coronavirus infection.
Based on the product, the global 3D cell culture market can be segmented into scaffold-based platforms, scaffold-free platforms, microchips, bioreactors, and others. Currently, scaffold-based platforms hold the majority of the total market share.
Based on the application, the global 3D cell culture market has been divided into cancer research, stem cell research, drug discovery, regenerative medicine, and others. Among these, cancer research currently exhibits a clear dominance in the market.
Based on the end user, the global 3D cell culture market can be categorized into biotechnology and pharmaceutical companies, contract research laboratories, academic institutes, and others. Currently, the biotechnology and pharmaceutical companies account for the largest market share.
On a regional level, the market has been classified into North America, Asia-Pacific, Europe, Latin America, and Middle East and Africa, where North America currently dominates the global market.
Some of the major players in the global 3D cell culture market include 3D Biotek LLC, Advanced Biomatrix Inc., Avantor Inc., CN Bio Innovations Limited, Corning Incorporated, Emulate Inc., InSphero AG, Lonza Group AG, Merck KGaA, Promocell GmbH, Synthecon Inc, and Thermo Fisher Scientific Inc.
REACH OUT TO US
Call us on
( US: +1-631-791-1145 )
( UK: +44-753-713-2163 )
( India: +91 120 433 0800 )
Drop us an email at